Literature DB >> 26882845

The use of MRI deformable image registration for CT-based brachytherapy in locally advanced cervical cancer.

Lauren M Tait1, David Hoffman1, Stanley Benedict1, Richard Valicenti1, Jyoti S Mayadev2.   

Abstract

PURPOSE: Incorporation of MRI into image-based brachytherapy (IBBT) is limited by logistics, reimbursement, and workflow demands. Our goal is to determine if deformable image registration (DIR) using a preimplantation MRI is feasible to construct a high-risk target volume during IBBT. METHODS AND MATERIALS: From 2010 to 2013, 20 patients were treated with high-dose-rate IBBT for cervical cancer. A preimplantation MRI was fused to the planning CT, and DIR was performed using MIM v6.1. The gross tumor volume (GTV) and high-risk clinical target volume were contoured on the MRI (HR-CTV MRI), and a separate high-risk clinical target volume was made from the deformable image registration of the preimplantation MRI to the planning CT (HR-CTV'). The treated target volume from the planning CT without the DIR or fusion (HR-CTV BT) was compared with the HR-CTV'. The geometric means of the GTV, HR-CTV MRI, HR-CTV', and HR-CTV BT were analyzed. Statistical analysis using Wilcoxon rank and analysis of variance were performed.
RESULTS: There was a significant larger difference between the GTV and the HR-CTV MRI, HR-CTV', and HR-CTV BT (p < 0.0001). There was also a significant difference between the HR-CTV MRI vs. the HR-CTV BT (p < 0.040). There was no significant difference between the HR-CTV MRI and HR-CTV'. DIR was advantageous in the setting of residual disease pre-IBBT.
CONCLUSIONS: DIR is feasible to define an HR-CTV for MRI-guided, CT IBBT. The HR-CTV MRI predicted a smaller treatment volume in comparison with the HR-CTV BT. DIR is limited by patient anatomy and is most beneficial in patients with gross disease. Published by Elsevier Inc.

Entities:  

Keywords:  Cervical cancer; HDR brachytherapy; Image-based brachytherapy; MRI

Mesh:

Year:  2016        PMID: 26882845     DOI: 10.1016/j.brachy.2016.01.002

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  5 in total

Review 1.  MRI in medical practice and its future use in radiation oncology. Resume of XXV GOCO Congress (Montpellier) 2017.

Authors:  Xavier Druet; Estrella Acosta Sanchez; Ken Soleakhena; Anne Laprie; Jordi Sáez; Stéphanie Nougaret; Olivier Riou; Elodie Rigal; Laura Kibranian; Miguel Palacios; Ismael Membrive
Journal:  Rep Pract Oncol Radiother       Date:  2019-06-05

Review 2.  How one institution overcame the challenges to start an MRI-based brachytherapy program for cervical cancer.

Authors:  Matthew M Harkenrider; Steven M Shea; Abbie M Wood; Bonnie Chinsky; Amishi Bajaj; Michael Mysz; Joseph H Yacoub; Ari Goldberg; Margaret Liotta; Ronald Potkul; Murat Surucu; John Roeske; William Small
Journal:  J Contemp Brachytherapy       Date:  2017-03-30

3.  COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation.

Authors:  Vonetta M Williams; Jenna M Kahn; Matthew M Harkenrider; Junzo Chino; Jonathan Chen; L Christine Fang; Emily F Dunn; Emma Fields; Jyoti S Mayadev; Ramesh Rengan; Daniel Petereit; Brandon A Dyer
Journal:  Brachytherapy       Date:  2020-04-21       Impact factor: 2.362

4.  Clinical value of MRI, serum SCCA, and CA125 levels in the diagnosis of lymph node metastasis and para-uterine infiltration in cervical cancer.

Authors:  Chao Ran; Jian Sun; Yunhui Qu; Na Long
Journal:  World J Surg Oncol       Date:  2021-12-09       Impact factor: 2.754

Review 5.  Dose Summation Strategies for External Beam Radiation Therapy and Brachytherapy in Gynecologic Malignancy: A Review from the NRG Oncology and NCTN Medical Physics Subcommittees.

Authors:  Hayeon Kim; Yongsook C Lee; Stanley H Benedict; Brandon Dyer; Michael Price; Yi Rong; Ananth Ravi; Eric Leung; Sushil Beriwal; Mark E Bernard; Jyoti Mayadev; Jessica R L Leif; Ying Xiao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-06-17       Impact factor: 7.038

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.